Trial Profile

Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dornase alfa (Primary)
Indications COVID 2019 infections; Inflammation; Multiple organ failure; Respiratory insufficiency
Focus Therapeutic Use
Acronyms DAMPEN COVID

Most Recent Events

26 May 2021 Planned End Date changed from 28 Feb 2021 to 28 Feb 2022.
26 May 2021 Planned primary completion date changed from 30 Nov 2020 to 30 Nov 2021.
19 Aug 2020 Planned End Date changed from 31 Jul 2020 to 28 Feb 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com